Chugai OTC Stock Market Sentiment

CHGCF
 Stock
  

USD 27.00  0.28  1.05%   

Chugai investor sentiment overview provides quick insight into current market opportunities from investing in Chugai Pharmaceutical. The current market sentiment together Chugai Pharmaceutical's historical and current headlines can help investors to time the market. Many technical investors use Chugai Pharmaceutical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Continue to Chugai Pharmaceutical Hype Analysis, Chugai Pharmaceutical Correlation and Chugai Pharmaceutical Performance.
  
Refresh
Chugai Pharmaceutical otc stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Chugai daily returns and investor perception about the current pice of Chugai Pharmaceutical as well as its diversification or hedging effects on your existing portfolios.

Chugai Latest Sentiment Indicators

200 Day MA
32.74
50 Day MA
28.43
52 Week Low
26.72
52 Week High
38.77
Beta
0.66
2 days ago at www.stockopedia.com         
Four clues to the quality of Chugai Pharmaceutical Co - Stockopedia
news
3 days ago at seekingalpha.com         
Verastem Stock Looking Increasingly Attractive - Seeking Alpha
seekingalpha News
over a week ago at www.morningstar.com         
Indian Morning Briefing Asian Markets Mostly Higher - Morningstar
Morningstar News at Macroaxis
over a week ago at finance.yahoo.com         
Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizu...
Yahoo News
over a week ago at www.marketscreener.com         
Chugai Pharmaceutical Obtains Regulatory Approval for Hemlibra for Additional Indication of Acquired...
news
over two weeks ago at finance.yahoo.com         
Bispecific Antibody Market Size 2022-2029 Global Industry Growth, Share, Demand Insights, Trends, Ke...
Yahoo News
over two weeks ago at www.marketscreener.com         
Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-1...
news
over three weeks ago at www.streetinsider.com         
US FDA approves Foundation Medicines FoundationOneCDx as a companion diagnostic for Roches Rozlytrek...
Street Insider News
over a month ago at www.marketscreener.com         
FDA approves Roches Evrysdi for use in babies under two months with spinal muscular atrophy - Market...
news
over a month ago at www.marketscreener.com         
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NM...
news
over a month ago at finance.yahoo.com         
Halozyme Completes Antares Pharma Acquisition - Yahoo Finance
Yahoo News
over a month ago at www.smartkarma.com         
Health Care Virtus Health, Yunkang Group, Aier Eye Hospital Group, Chugai Pharmaceutical, Eris Lifes...
news
over a month ago at www.prnewswire.com         
Hart-Scott-Rodino Waiting Period Expires for Halozymes Acquisition of Antares Pharma - PR Newswire
prnewswire News
over a month ago at www.prnewswire.com         
Halozyme Reports First Quarter 2022 Results - PR Newswire
prnewswire News
over a month ago at www.digitaljournal.com         
Neuromyelitis Optics Therapy Market Size and Future Prospects Alexion Pharmaceuticals Inc., Chugai P...
news
There is far too much social signal, news, headlines, and media speculation about Chugai Pharmaceutical that is available to investors today. That information is available publicly through Chugai media outlets and privately through word of mouth or via Chugai internal channels. However, regardless of the origin, that massive amount of Chugai data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Chugai Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Chugai Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Chugai Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Chugai Pharmaceutical alpha.

Chugai Pharmaceutical Performance against DOW

 Price Growth (%)  
      Timeline 
1
Human Granulocyte Colony-stimulating Factor Market Forecast ...04/26/2022
2
PROTARA THERAPEUTICS, INC. Managements Discussion and Analys...05/05/2022
3
Hart-Scott-Rodino Waiting Period Expires for Halozymes Acqui...05/12/2022
4
Protara Therapeutics Announces Trials in Progress Poster Pre...05/26/2022
5
Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first P...06/15/2022
6
Galderma Announces Positive Data From Phase III Trial, Demon...06/21/2022
Continue to Chugai Pharmaceutical Hype Analysis, Chugai Pharmaceutical Correlation and Chugai Pharmaceutical Performance. Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Chugai OTC Stock analysis

When running Chugai Pharmaceutical price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Is Chugai Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chugai Pharmaceutical. If investors know Chugai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chugai Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
1.78
Market Capitalization
44.4 B
Quarterly Revenue Growth YOY
1.14
Return On Assets
0.25
Return On Equity
0.35
The market value of Chugai Pharmaceutical is measured differently than its book value, which is the value of Chugai that is recorded on the company's balance sheet. Investors also form their own opinion of Chugai Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Chugai Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chugai Pharmaceutical's market value can be influenced by many factors that don't directly affect Chugai Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chugai Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine Chugai Pharmaceutical value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chugai Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.